Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors.

Trial Profile

Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Belinostat (Primary)
  • Indications Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors TopoTarget
  • Most Recent Events

    • 11 Nov 2011 Interim results will be presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH-2011).
    • 28 Apr 2011 Planned end date changed from 1 Dec 2010 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 28 Apr 2011 Planned end date changed from 1 Dec 2010 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top